IPO - Profile

Summary

We are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. In approximately three and a half years, we have efficiently developed or in-licensed a pipeline of seven distinct programs More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$29.91 21,000,000 Positive High 19.3%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • KPMG LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 07 Jan, 2021

Offer 08 Jan, 2021

Look Ahead

Lock Up Expiry Jul 08, 2021

IPO Terms

Offer Price $29.91
Offer Size 21M

Market Sentiments

Stock Price